This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delmas, P. D. Articles by Eastell, R. Search for Related Content PubMed PubMed Citation Articles by Delmas, P. D. Articles by Eastell, R.

Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial

University of Claude Bernard of Lyon (P.D.D.), Hôpital Edouard Herriot, Service de Rhumatologie et de Pathologie Osseuse, Lyon 69437, France; Department of Medicine (K.E.E.), Minneapolis VA Medical Center, Minneapolis, Minnesota 55417; St. Joseph’s Hospital (J.D.A.), McMaster University, Hamilton, Ontario, L8N 1Y2 Canada; Lilly Research Laboratories (K.D.H., S.S., W.W.), Eli Lilly and Company, Indianapolis, Indiana 46285; Institute of Internal Medicine and Medical Pathology (C.G.), University of Siena, 53100 Siena, Italy; Bone/Cartilage Metabolism Unit (J.-Y.R.), Centre Hôpital Universitaire Centre-Ville, Liege 04020, Belgium; Department of Internal Medicine (H.A.P.P.), Erasmus University Medical School, Rotterdam DR 3000, The Netherlands; Osteoporosis Research Center (R.R.R.), Creighton University, Omaha, Nebraska 68131; Departments of Medicine (S.T.H.), Epidemiology and Biostatistics (D.M.B.), and Musculoskeletal Radiology (H.K.G.), University of California at San Francisco, San Francisco, California 94117; and Northern General Hospital (R.E.), Clinical Science Center, University of Sheffield, Sheffield, Yorkshire S5 7AU United Kingdom

Address all correspondence and requests for reprints to: Pierre D. Delmas, M.D., Ph.D., University Claude Bernard of Lyon, Hôpital Edouard Herriot, Pavillon F, Lyon, Cedex 03 69437, France. E-mail: . delmas{at}lyon151.inserm.fr

Abstract

The Multiple Outcomes of Raloxifene Evaluation trial studied 7705 postmenopausal women with osteoporosis randomized to placebo, or raloxifene 60 or 120 mg/d [JAMA 282(1999): 637]. This report assesses the efficacy of raloxifene on the long-term cumulative incidence new vertebral fractures through 4 yr.

New vertebral fractures was assessed from radiographs taken at baseline, yr 2–4. The primary analysis was the cumulative incidence of new vertebral fractures through 4 yr. A posthoc analysis compared the vertebral fracture risk in yr 4 alone with that observed in the first 3 yr.

The 4-yr cumulative relative risks (RR) for one or more new vertebral fractures were 0.64 [95% confidence interval (CI) 0.53, 0.76] with raloxifene 60 mg/d and 0.57 (95% CI 0.48, 0.69) with raloxifene 120 mg/d. In yr 4 alone, raloxifene 60 mg/d reduced the new vertebral fracture risk by 39% [RR 0.61 (95% CI 0.43, 0.88)], which was not found to be significantly different from the RR observed in the first 3 yr in both raloxifene groups, irrespective of prevalent fracture status. The nonvertebral fracture risk was not significantly reduced [RR 0.93 (95% CI 0.81, 1.06)]. The safety profile after 4 yr was similar to that observed after 3 yr.

Raloxifene 60 and 120 mg/d through 4 yr decreased the cumulative risk of new vertebral fractures in postmenopausal women with osteoporosis. The decreased vertebral fracture risk in yr 4 alone was not different from that observed in the first 3 yr.

This article has been cited by other articles:

				L. Gehrig, J. Lane, and M. I. O'Connor Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons J. Bone Joint Surg. Am., June 1, 2008; 90(6): 1362 - 1374. [Full Text] [PDF]

				H. Liu, N. M. Paige, C. L. Goldzweig, E. Wong, A. Zhou, M. J. Suttorp, B. Munjas, E. Orwoll, and P. Shekelle Screening for Osteoporosis in Men: A Systematic Review for an American College of Physicians Guideline Ann Intern Med, May 6, 2008; 148(9): 685 - 701. [Abstract] [Full Text] [PDF]

				J. S. Barrett, M. J. Fossler, K. D. Cadieu, and M. R. Gastonguay Pharmacometrics: A Multidisciplinary Field to Facilitate Critical Thinking in Drug Development and Translational Research Settings J. Clin. Pharmacol., May 1, 2008; 48(5): 632 - 649. [Abstract] [Full Text] [PDF]

				M. R. Allen, H. A. Hogan, W. A. Hobbs, A. S. Koivuniemi, M. C. Koivuniemi, and D. B. Burr Raloxifene Enhances Material-Level Mechanical Properties of Femoral Cortical and Trabecular Bone Endocrinology, August 1, 2007; 148(8): 3908 - 3913. [Abstract] [Full Text] [PDF]

				T. J. Powles, S. Ashley, A. Tidy, I. E. Smith, and M. Dowsett Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial J Natl Cancer Inst, February 21, 2007; 99(4): 283 - 290. [Abstract] [Full Text] [PDF]

				H.J. Cloft and M.E. Jensen Kyphoplasty: An Assessment of a New Technology AJNR Am. J. Neuroradiol., February 1, 2007; 28(2): 200 - 203. [Abstract] [Full Text] [PDF]

				E. S. Meadows, J. Stock, and J. A. Johnston Commentary on Mobley and Others: Importance of Assumptions About VTE Mortality in Modeling the Cost-effectiveness of Osteoporosis Therapies. Med Decis Making, November 1, 2006; 26(6): 633 - 635. [PDF]

				A.T. Trout and D.F. Kallmes Does Vertebroplasty Cause Incident Vertebral Fractures? A Review of Available Data AJNR Am. J. Neuroradiol., August 1, 2006; 27(7): 1397 - 1403. [Abstract] [Full Text] [PDF]

				E. Barrett-Connor, L. Mosca, P. Collins, M. J. Geiger, D. Grady, M. Kornitzer, M. A. McNabb, N. K. Wenger, and the Raloxifene Use for The Heart (RUTH) Trial Inve Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med., July 13, 2006; 355(2): 125 - 137. [Abstract] [Full Text] [PDF]

				H. Liu, K. Michaud, S. Nayak, D. B. Karpf, D. K. Owens, and A. M. Garber The Cost-effectiveness of Therapy With Teriparatide and Alendronate in Women With Severe Osteoporosis. Arch Intern Med, June 12, 2006; 166(11): 1209 - 1217. [Abstract] [Full Text] [PDF]

				S. Nayak, I. Olkin, H. Liu, M. Grabe, M. K. Gould, I. E. Allen, D. K. Owens, and D. M. Bravata Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis. Ann Intern Med, June 6, 2006; 144(11): 832 - 841. [Abstract] [Full Text] [PDF]

				S. Olivier, P. Close, E. Castermans, L. de Leval, S. Tabruyn, A. Chariot, M. Malaise, M.-P. Merville, V. Bours, and N. Franchimont Raloxifene-Induced Myeloma Cell Apoptosis: A Study of Nuclear Factor-{kappa}B Inhibition and Gene Expression Signature Mol. Pharmacol., May 1, 2006; 69(5): 1615 - 1623. [Abstract] [Full Text] [PDF]

				L. R. Mobley, T. J. Hoerger, J. S. Wittenborn, D. A. Galuska, and J. K. Rao Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making, March 1, 2006; 26(2): 194 - 206. [Abstract] [PDF]

				D. Michalska, J. J. Stepan, B. R. Basson, and I. Pavo The Effect of Raloxifene after Discontinuation of Long-Term Alendronate Treatment of Postmenopausal Osteoporosis J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 870 - 877. [Abstract] [Full Text] [PDF]

				D. M. Antoniucci, E. Vittinghoff, T. Blackwell, D. M. Black, and D. E. Sellmeyer Vitamin D Insufficiency Does Not Affect Bone Mineral Density Response to Raloxifene J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4566 - 4572. [Abstract] [Full Text] [PDF]

				M. L. Bouxsein, J. Kaufman, L. Tosi, S. Cummings, J. Lane, and O. Johnell Recommendations for Optimal Care of the Fragility Fracture Patient to Reduce the Risk of Future Fracture J. Am. Acad. Ortho. Surg., November 1, 2004; 12(6): 385 - 395. [Abstract] [Full Text] [PDF]

				Cholecystitis, Biliary Tract Surgery, and Pancreatitis Obstet. Gynecol., October 1, 2004; 104(4_suppl): 17S - 24S. [Full Text] [PDF]

				Osteoporosis Obstet. Gynecol., October 1, 2004; 104(4_suppl): 66S - 76S. [Full Text] [PDF]

				P. Neven, D. Quail, M. Levrier, F. Aguas, H. S. The, C. De Geyter, M. D. Glant, H. Beck, B. Bosio-LeGoux, H. Schmitt, et al. Uterine Effects of Estrogen Plus Progestin Therapy and Raloxifene: Adjudicated Results From the EURALOX Study Obstet. Gynecol., May 1, 2004; 103(5): 881 - 891. [Abstract] [Full Text] [PDF]

				R. A. Adler and M. C. Hochberg Suggested Guidelines for Evaluation and Treatment of Glucocorticoid-Induced Osteoporosis for the Department of Veterans Affairs Arch Intern Med, November 24, 2003; 163(21): 2619 - 2624. [Abstract] [Full Text] [PDF]

				G. Boivin, P. Lips, S. M. Ott, K. D. Harper, S. Sarkar, K. V. Pinette, and P. J. Meunier Contribution of Raloxifene and Calcium and Vitamin D3 Supplementation to the Increase of the Degree of Mineralization of Bone in Postmenopausal Women J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4199 - 4205. [Abstract] [Full Text] [PDF]

				A. W. C. Kung, H.-T. Chao, K.-E. Huang, A. G. Need, N. Taechakraichana, F.-H. Loh, F. Gonzaga, U. Sriram, N. M. N. Ismail, A. Farooqi, et al. Efficacy and Safety of Raloxifene 60 Milligrams/Day in Postmenopausal Asian Women J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3130 - 3136. [Abstract] [Full Text] [PDF]